Well, I would say that the previous marketcap (before the deal) was already baking in something other than continued losses, no?
regarding the derisking part, I dont quite understand it. If the company keeps its costs for the clinical trials + admin at 24M, to justify the current price (following my previous logic), the revenue coming from the clinical trials would have to be $30 million. I'm not saying it wont be even higher, but there was already one time when things didn't go according to plan,right? Can that happen again?
Well, I would say that the previous marketcap (before the deal)...
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
-0.015(1.60%) |
Mkt cap ! $157.9M | |||
| Open | High | Low | Value | Volume |
| 92.5¢ | 95.0¢ | 91.5¢ | $157.5K | 170.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3377 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.5¢ | 246 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| CGS (ASX) Chart |